Cytek Biosciences (CTKB) Income from Continuing Operations (2020 - 2026)
Cytek Biosciences (CTKB) posted Income from Continuing Operations of 18873000.0 for Q1 2026, up 57.14% on a QoQ basis from 44029000.0 in Q4 2025, and down 65.52% year-over-year from 54741782.24 in Q1 2025.
Cytek Biosciences (CTKB) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Cytek Biosciences' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 18873000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 65.52% year-over-year to 18873000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 73954000.0 (down 555.85% YoY) and the FY2025 annual result came in at 66539000.0, down 1005.3% from the prior year.
- Income from Continuing Operations was 18873000.0 for Q1 2026 at Cytek Biosciences, up from 44029000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 9603000.0 in Q4 2024 and bottomed at 44029000.0 in Q4 2025.
- A 5-year average of 5948647.06 and a median of 5469000.0 in 2025 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 419.14% in 2022, while the deepest fall reached 2215.69% in 2022.
- Cytek Biosciences' Income from Continuing Operations stood at 3718000.0 in 2022, then jumped by 48.01% to 5503000.0 in 2023, then soared by 74.5% to 9603000.0 in 2024, then plunged by 558.49% to 44029000.0 in 2025, then surged by 57.14% to 18873000.0 in 2026.
- Business Quant data shows CTKB's Income from Continuing Operations at 18873000.0 in Q1 2026, 44029000.0 in Q4 2025, and 5469000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 380.70 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 199.50 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 273.95 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 411.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Cytek Biosciences | 586.89 Mn | 521.19 Mn | 21.25 Mn | -18.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -18.87 Mn |
| Dec 31, 2025 | -44.03 Mn |
| Sep 30, 2025 | -5.47 Mn |
| Jun 30, 2025 | -5.58 Mn |
| Mar 31, 2025 | -11.40 Mn |
| Dec 31, 2024 | 9.60 Mn |
| Sep 30, 2024 | 957,000.00 |
| Jun 30, 2024 | -10.43 Mn |
| Mar 31, 2024 | -6.19 Mn |
| Dec 31, 2023 | 5.50 Mn |
| Sep 30, 2023 | -6.46 Mn |
| Jun 30, 2023 | -4.40 Mn |
| Mar 31, 2023 | -6.84 Mn |
| Dec 31, 2022 | 3.72 Mn |
| Sep 30, 2022 | 1.63 Mn |
| Jun 30, 2022 | -702,000.00 |
| Mar 31, 2022 | -2.16 Mn |
| Dec 31, 2021 | -1.17 Mn |
| Sep 30, 2021 | 1.42 Mn |
| Jun 30, 2021 | 2.67 Mn |